These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24529133)

  • 21. Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women.
    Onat A; Hergenç G; Karabulut A; Albayrak S; Can G; Kaya Z
    Metabolism; 2007 Oct; 56(10):1356-62. PubMed ID: 17884445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Disorders of lipid metabolism in insulin resistance].
    Müller-Wieland D; Krone W
    Herz; 1995 Feb; 20(1):33-46. PubMed ID: 7713475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
    Rader DJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome: diabetes and cardiovascular disease.
    Gupta S; Gupta BM
    Indian Heart J; 2006; 58(2):149-52. PubMed ID: 18989060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controversies in dyslipidemias: atheroprevention in diabetes and insulin resistance.
    Brinton EA
    Ann N Y Acad Sci; 2005 Dec; 1055():159-78. PubMed ID: 16387723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin prevents type 2 diabetes mellitus--an experimental study.
    Madhu SV; Aslam M; Galav V; Bhattacharya SK; Jafri AA
    Eur J Pharmacol; 2014 Apr; 728():135-40. PubMed ID: 24530420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of insulin resistance in the obese with metabolic syndrome.
    Manu P; Tsang J; Napolitano BA; Lesser ML; Correll CU
    Eur J Intern Med; 2010 Oct; 21(5):409-13. PubMed ID: 20816595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dyslipidemia and oxidative stress in PCOS.
    Macut D; Bjekić-Macut J; Savić-Radojević A
    Front Horm Res; 2013; 40():51-63. PubMed ID: 24002405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
    Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome.
    Sniderman AD; Faraj M
    Curr Opin Lipidol; 2007 Dec; 18(6):633-7. PubMed ID: 17993808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HDLs, diabetes, and metabolic syndrome.
    Vollenweider P; von Eckardstein A; Widmann C
    Handb Exp Pharmacol; 2015; 224():405-21. PubMed ID: 25522996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
    Chong T; Naples M; Federico L; Taylor D; Smith GJ; Cheung RC; Adeli K
    Atherosclerosis; 2006 Mar; 185(1):21-31. PubMed ID: 16002078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model of intestinal chylomicron over-production and ezetimibe treatment: impact on the retention of cholesterol in arterial vessels.
    Mangat R; Warnakula S; Wang Y; Russell JC; Uwiera R; Vine DF; Proctor SD
    Atheroscler Suppl; 2010 Jun; 11(1):17-24. PubMed ID: 20471328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apolipoprotein A-II: evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis.
    Chan DC; Ng TW; Watts GF
    Ann Med; 2012 Jun; 44(4):313-24. PubMed ID: 21501035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population.
    Florez H; Mendez A; Casanova-Romero P; Larreal-Urdaneta C; Castillo-Florez S; Lee D; Goldberg R
    Atherosclerosis; 2006 Sep; 188(1):134-41. PubMed ID: 16298371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin use in the metabolic syndrome.
    Lundbye JB; Thompson PD
    Curr Atheroscler Rep; 2005 Feb; 7(1):17-21. PubMed ID: 15683597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review.
    Bjornstad P; Eckel RH
    Curr Diab Rep; 2018 Oct; 18(12):127. PubMed ID: 30328521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.